Targeting Diseased Tissues by pHLIP Insertion at Low Cell Surface pH by Andreev, Oleg A. et al.
University of Rhode Island
DigitalCommons@URI
Physics Faculty Publications Physics
2014
Targeting Diseased Tissues by pHLIP Insertion at
Low Cell Surface pH
Oleg A. Andreev
University of Rhode Island, andreev@uri.edu
Donald M. Engelman
See next page for additional authors
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.
Follow this and additional works at: https://digitalcommons.uri.edu/phys_facpubs
This Article is brought to you for free and open access by the Physics at DigitalCommons@URI. It has been accepted for inclusion in Physics Faculty
Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
Andreev OA, Engelman DM and Reshetnyak YK (2014) Targeting diseased tissues by pHLIP insertion at low cell surface pH. Front.
Physiol. 5:97. doi: 10.3389/fphys.2014.00097
Available at: http://dx.doi.org/10.3389/fphys.2014.00097
Authors
Oleg A. Andreev, Donald M. Engelman, and Yana K. Reshetnyak
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/phys_facpubs/54
REVIEW ARTICLE
published: 13 March 2014
doi: 10.3389/fphys.2014.00097
Targeting diseased tissues by pHLIP insertion at low cell
surface pH
Oleg A. Andreev1, Donald M. Engelman2 and Yana K. Reshetnyak1*
1 Department of Physics, University of Rhode Island, Kingston, RI, USA
2 Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT, USA
Edited by:
Ebbe Boedtkjer, Aarhus University,
Denmark
Reviewed by:
Annarosa Arcangeli, University of
Florence, Italy
Luis M. S. Loura, University of
Coimbra, Portugal
*Correspondence:
Yana K. Reshetnyak, Department
of Physics, University of Rhode
Island, 2 Lippitt Rd., Kingston,
RI 02881, USA
e-mail: reshetnyak@mail.uri.edu
The discovery of the pH Low Insertion Peptides (pHLIPs®) provides an opportunity to
develop imaging and drug delivery agents targeting extracellular acidity. Extracellular
acidity is associated with many pathological states, such as those in cancer, ischemic
stroke, neurotrauma, infection, lacerations, and others. The metabolism of cells in injured
or diseased tissues often results in the acidification of the extracellular environment, so
acidosis might be useful as a general marker for the imaging and treatment of diseased
states if an effective targeting method can be developed. The molecular mechanism of
a pHLIP peptide is based on pH-dependent membrane-associated folding. pHLIPs, being
moderately hydrophobic peptides, have high affinities for cellular membranes at normal
pH, but fold and insert across membranes at low pH, allowing them to sense pH at
the surfaces of cells in diseased tissues, where it is the lowest. Here we discuss the
main principles of pHLIP interactions with membrane lipid bilayers at neutral and low pHs,
the possibility of tuning the folding and insertion pH by peptide sequence variation, and
potential applications of pHLIPs for imaging, therapy and image-guided interventions.
Keywords: universal health test, imaging, nanotechnology, drug delivery
Many diseases such as cancer (solid tumors), ischemia, stroke,
infection and others lead to the development of local hypoxia
and acidosis. The extracellular acidosis results from enhanced use
of glycolysis and production of carbonic and lactic acids, which
are intensively pumped out cells to keep intracellular pH near
neutral. Acids produced in this way accumulate in extracellular
spaces since there is poor blood circulation in diseased tissues. As
a consequence, a reversed membrane pH gradient is formed: the
extracellular pH (pHe) in diseased tissue is lower than the intra-
cellular pH (pHi) compared with normal tissues (Gerweck and
Seetharaman, 1996; Raghunand et al., 1999). Extracellular acid-
ity might serve as a general marker for detecting and targeting
diseased tissue. However, such a strategy is challenging, since the
bulk extracellular pH in diseased tissue is just 0.5–0.8 pH units
lower than the extracellular pH in healthy tissue (Hashim et al.,
2011). From a biological standpoint the change is significant, and
alters the functions and survival of cells. At the same time, from
a chemical standpoint the change is small, so very precise tun-
ing of chemical properties would be needed in a targeting agent.
But, an important point that is often overlooked is that the pH is
lowest at the surfaces of cells compared to the bulk extracellular
pH (Chiche et al., 2010) and increases with distance from mem-
brane, and becoming normal in the vicinity of blood vessels. So,
the average pH in tissue is less informative than the pH at cellular
surfaces, which might be the main target for the development of
pH-sensitive agents. We have been developing a novel class of pH-
sensitive delivery agents, pHLIP® s (pH Low Insertion Peptides),
which are moderately hydrophobic peptides that can insert into
membranes at mild acidic pHs, and which locate themselves at
cell surfaces where the pH is lowest (Andreev et al., 2009, 2010a).
MOLECULAR MECHANISM OF pHLIPs INTERACTIONWITH
MEMBRANE
Peptides of the pHLIP family consist of flanking and transmem-
brane (TM) sequences (Figure 1A). The TM part is essential
for the interaction with the membrane. The flanking-1 sequence
is instrumental for peptide solubility. It usually contains polar
and charged residues (Hunt et al., 1997; Reshetnyak et al.,
2007; Barrera et al., 2011). The membrane-inserting flanking-2
sequence also can contribute to solubility, and affects the rates
of peptide insertion and exit from the membrane (Karabadzhak
et al., 2012). In general, peptides of the pHLIP family con-
tain a mixture of natural and/or non-natural amino acids that
are hydrophobic and protonatable at low pH. The presence
of hydrophobic residues ensures that the peptide maintains an
affinity to membrane. The presence of protonatable residues
is required (i) for guaranteeing solubility at neutral pH, when
they carry negative charges, and (ii) for the enhancement of
hydrophobicity at low pH, when the equilibrium is shifted toward
protonation.
At neutral and high pH, pHLIP is monomeric and largely
unstructured. In the presence of a membrane or lipid bilayer,
peptides in aqueous solution coexist with unstructured pep-
tides adsorbed to the surface (Figure 1B). The fraction of the
adsorbed peptides is controlled by the lipid:peptide ratio, which
in turn affects diffusion of the peptide onmembrane surface (Guo
and Gai, 2010). Lowering the pH shifts the equilibrium toward
folding, membrane insertion, and formation of a TM helix. A
subsequent increase of pH promotes the reverse reaction: unfold-
ing of the TM helix and its exit from the bilayer interior. Thus,
peptide association with the membrane is distinguishable from
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FIGURE 1 | Schematic presentation of pHLIP interaction with lipid
bilayer of membrane. Sequence of the WT pHLIP (A). At high and neutral
pHs pHLIP is associated with the lipid bilayer of membrane. Negative charges
of Asp, Glu, and C-terminus prevent partition of the peptide into bilayer. After
a drop of the pH, some Asp/Glu residues are protonated, leading to an
increase of overall peptide hydrophobicity that triggers deeper partitioning
into the bilayer and the formation of an interfacial helix, which results in the
distortion of the bilayer. Protonation of Asp/Glu at the inserting end
(C-terminus) of the peptide leads to the formation of a transmembrane helix,
which reduces the bilayer distortion (B).
the process of peptide partitioning into the bilayer. The latter is
accompanied by a coil-helix transition and triggered by a drop
in pH. Peptides consisting of L- or D-amino acids show pH-
dependent tumor cell targeting in vitro and in vivo confirming
that the mechanism is TM helix formation (right or left handed,
respectively), and that it does not depend on any specific recog-
nition event such as binding to a receptor (Andreev et al., 2007;
Macholl et al., 2012). The adsorption of pHLIPs to a model
membrane surface is accompanied by an energy release of 5–6
kcal/mol, and the insertion process is accompanied by an addi-
tional energy release of about 1.8–2.5 kcal/mol. Hence the bilayer
affinity of the peptide is 30–50 times higher at low pH than at
high pH (Reshetnyak et al., 2008; Weerakkody et al., 2013). The
pHLIP insertion results from the protonation of Asp/Glu residues
in the TM part of the sequence and its (inserting) flanking-2 end.
Carboxyl group protonation leads to an increase in hydrophobic-
ity, which, in turn, triggers TM formation across the hydrophobic
bilayer interior (Andreev et al., 2007; Musial-Siwek et al., 2010).
Since the surface bound peptide is located at an intermediate
zone between polar (aqueous) and non-polar (membrane) envi-
ronments, the pK for the protonation of Asp and Glu residues
is significantly shifted to higher pH values (Harris and Turner,
2002), and the apparent pK of pHLIP insertion can vary from 4.5
to 6.5 (Reshetnyak et al., 2007; Musial-Siwek et al., 2010; Barrera
et al., 2011; Weerakkody et al., 2013).
pHLIP insertion is predominantly uni-directional. In most
instances it is the C-terminus (flanking-2 end) that propagates
across the bilayer and comes out in the cytoplasm (except of the
reverse pHLIP sequence with an acetylated N-terminus), while
the N-terminus stays in the extracellular region (Reshetnyak et al.,
2006; Thevenin et al., 2009). The propagation into the bilayer of
the positively charged N-terminal at the flanking-1 end is ener-
getically unfavorable compared to partition of the C-terminal at
the flanking-2 end. The latter becomes electrically neutral after
the protonation of COO− groups at low pH (Karabadzhak et al.,
2012), while the positive charge is difficult to deprotonate and
its passage is resisted by the membrane dipole potential. Peptide
insertion into the membrane can be sub-divided into two distinct
steps: (i) the formation of an interfacial helix and (ii) the move-
ment of the helix across the bilayer to adopt a TMorientation. The
timescale for the first process is about 0.1 s, while for the second
process it may vary from 0.1 up to 100 s (Andreev et al., 2010b;
Karabadzhak et al., 2012), depending on several factors such as
(i) the total number of protonatable residues in the sequence, (ii)
their pK values, (iii) the presence of protonatable residues and/or
polar cargo molecules at the peptide inserting end, and (iv) the
compositional properties of the bilayer. The timescale for the pep-
tide to exit from the bilayer varies from several milliseconds to
seconds. It is also affected by the number of protonatable residues
at the peptide inserting end, especially in the case of insertion into
live cells, where the pH in the cytoplasm is 7.2–7.4. The Asp and
Glu residues are moved across a bilayer while protonated, and in
the cytoplasm they become de-protonated, i.e., negatively charged
at pH7.2–7.4 and so serve as anchors for the peptide across a cell
membrane, reducing significantly the rate of peptide exit from the
bilayer. Thus, the number of protonatable groups on the peptide
inserting end slows both insertion and exit rates.
The properties of the lipid bilayer itself play an important
role in the process of peptide insertion. At neutral pH, when a
pHLIP is unstructured and associated with the outer leaflet of the
lipid bilayer, it creates some tension and distortion of the bilayer
(Figure 1B). However, due to the fact that the unstructured
polypeptide cannot propagate very deep into the bilayer and due
to the flexibility of the unstructured polypeptide at the surface of
the membrane at high pH, the distortion of the lipid bilayer is not
sufficient to render state II, which is thermodynamically stable.
However, when the peptide folds and adopts a more rigid, helical
structure on the membrane surface (interfacial helical interme-
diate) the perturbation of the lipids is locally increased. The
perturbation favors insertion, since a TM configuration is more
compatible with the bilayer.
pHLIP, in contrast to cell-penetrating peptides, stays in the
cellular membrane after insertion, translocating one end into
the cytoplasm and leaving the other end in the extracellular
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space. Therefore, the peptide possesses dual delivery capabili-
ties: it can tether cargo molecules to cell surfaces and/or it can
inject and release cell-impermeable cargo molecules into cell
cytoplasms (Andreev et al., 2009). In the first scenario, a cargo
molecule, such as an imaging agent, is attached to the pHLIP’s
N-terminus, remaining on the cell surface after pHLIP insertion.
Transmembrane delivery by pHLIP is based on translocation of
polar cargo molecules attached to the C-terminus, using a bond
that is stable outside the cell, but cleaved in the cytoplasm. In
addition, facilitator or quencher molecules can be attached to the
C-terminal part of the peptide together with cargo and/or imag-
ing agents (An et al., 2010; Wijesinghe et al., 2011). The chemical
conjugation of various cargo molecules to pHLIPs is straightfor-
ward, since Lys and/or Cys residues, as well as other chemical
functional moieties, can easily be included in the synthesis of the
peptide.
TARGETING OF ACIDIC DISEASED TISSUE
Cancer cells acquire extensive genetic alterations as they divide in
a tumor, including epigenetic regulation sites, point mutations,
gene deletions, gene duplications, and chromosomal rearrange-
ments. These changes are heterogeneously distributed within a
single tumor (Gillies et al., 2012). The heterogeneity of expres-
sion of particular biomarkers at cell surfaces within a tumor and
between tumors significantly reduces the effectiveness of agents
that target specific biomarkers. On the other hand, low extracel-
lular pH, which is a hallmark of tumors and other pathological
states, may provide a target independent of tumor heterogeneity,
so agents like pHLIP are worth exploring.
The thermodynamics and kinetics of the pHLIP-membrane
interaction predict preferential accumulation in acidic tissues.
Indeed, pHLIP peptides conjugated with fluorescent dyes demon-
strate excellent in vivo targeting of tumors of various ori-
gins (Andreev et al., 2007; Reshetnyak et al., 2011), ischemic
myocardium (Sosunov et al., 2013), sites of inflammatory arthri-
tis (Andreev et al., 2007), infection (Li et al., 2013) and ex
vivo staining of cancerous tissue on biopsy samples (Loja et al.,
2013). Clinical imaging modalities such as PET (positron emis-
sion tomography) and SPECT (single-photon emission computed
tomography) also show tumor targeting by pHLIP-based probes
(Vavere et al., 2009; Daumar et al., 2012; Macholl et al., 2012).
pHLIPs consisting of D-amino acids have the same bilayer inter-
actions as the L-amino acid versions, and show enhanced sta-
bility in vivo. Targeting of tumor acidity by pHLIP is correlated
with MRS (magnetic resonance spectroscopy) measurements of
low extracellular pH in tumors on live animals (Vavere et al.,
2009). The extracellular acidity in tumors can be modulated
by co-injection of glucose (which increases acidity through the
Warburg effect) or feeding animals with bicarbonate water (which
decreases acidity), resulting in enhanced or reduced pHLIP tar-
geting of tumors, respectively (Vavere et al., 2009; Reshetnyak
et al., 2011; Han et al., 2013). Analysis of pHLIP distribution
in tumors over time shows that pHLIP can stay in tumors for
several days, that tumor borders can be determined with high
accuracy and that pHLIP is localized at tumor cell membranes
(Segala et al., 2009; Reshetnyak et al., 2011). These properties sug-
gest that fluorescent pHLIP-based agents could be used in image
guided resections of tumors during surgery and in analysis of
tissue samples.
Adaptation to hypoxia and acidosismay represent key events in
the transition from in situ to invasive cancer (Gatenby and Gillies,
2007). Metastatic tumors, which have been shown to be more
acidic, are labeled more effectively by pHLIP than non-metastatic
ones (Reshetnyak et al., 2011). Further, ex vivo staining of biopsy
samples correlates with stages of tumor development. The sam-
ples of normal tissue including those with chronic inflammation
are not stained by pHLIP (Loja et al., 2013). Thus, there may
be an opportunity to predict tumor invasiveness and distinguish
aggressive tumor phenotypes. In addition to the targeting of pri-
mary tumors, the targeting of metastatic lesions by pHLIP has
been demonstrated, and very small tumors (∼1mm3) can be tar-
geted (Reshetnyak et al., 2011). Recently we introduced a family of
rationally designed pHLIP variants and demonstrated that tuning
by variations of the peptide sequence and, as a result, the physical
and chemical properties of peptide-membrane interactions, can
modulate tumor targeting, blood clearance, and biodistribution
(Weerakkody et al., 2013).
Since acidosis of different magnitudes is a general feature
of a number of pathological states, and since the insertion pK
of pHLIPs can be adjusted by sequence changes, a “universal
health test” might be developed based on imaging by a spec-
trum of pHLIPs with different pKs. Various diseases might be
identified at once and, each suspicious acidic spot could be
investigated/diagnosed further.
pHLIP AS A SINGLE-MOLECULE TRANSPORTER
While targeting of diseased tissue is useful for imaging and diag-
nosis, an exciting use of pHLIP is for treatment using transport of
an agent into a cell, where it can reach its cytoplasmic or nuclear
target. Most inhibitors and all gene targeting agents are highly
polar, and often, are charged molecules with extremely lim-
ited plasma membrane permeability. Several different approaches
might be employed to move such molecules into a cell:
- modification of a drug molecule to reduce its polarity and
enhance membrane-penetration;
- use of various nano-carriers;
- use of cell-penetrating peptides.
In conventional drug design and discovery the Lipinski rules of
five (and other, related concepts) are widely used to guide molec-
ular designs. The rules postulate that a successful drug should be
hydrophobic and small in order to traverse membranes and reach
cytoplasmic targets (e.g., the logarithm of the octanol-water par-
tition coefficient LogPo/w is −0.4 to +5.6 and the MW is 160
to 480 gmol−1) (Lipinski et al., 2001). There are several prob-
lems associated with this approach: (i) in some cases, it is difficult
or even impossible to convert the polar/charged molecule into a
hydrophobic one; (ii) modified drugs may lose their potency; (iii)
drugs designed in this way will indiscriminately enter all cells they
encounter, reducing effective concentrations in diseased areas and
inducing side effects. The side effects can be especially devastat-
ing for cancer treatments, since the majority of the drugs are toxic
molecules.
www.frontiersin.org March 2014 | Volume 5 | Article 97 | 3
Andreev et al. Targeting acidic diseased tissue
Various nanosized drug-delivery vehicles including, but
not limited to organic or inorganic nanoparticles, lipo-
somes, micelles, viral particles, polymers, dendrimers, and oth-
ers, have been designed for complexation or encapsulation
of polar/charged therapeutic molecules. Nano-carriers usually
are multifunctional, and targeting, imaging and therapeutic
molecules can be combined in a single nano-carrier (Ferrari,
2005; Davis et al., 2008; Gindy and Prud’homme, 2009; Cheng
et al., 2012; Han et al., 2013). Some targeting of vascularized
tumors can result from the enhanced permeability of tumor ves-
sels, resulting in preferential nanoparticle retention. Despite the
advantages, there are significant limitations related to the use of
nano-sized carriers, such as complexity and difficulty inmanufac-
turing, reduced stability, potential toxicity of some nanomaterials,
and reduced tumor-penetration ability. Significantly, all nanocar-
riers enter cells via one of the endocytotic routes, which are
usually of low efficacy due to the entrapment of therapeutic
molecule in the endosomal/lysosomal compartments.
Cell-penetrating, positively-charged peptides such as TAT [a
peptide derived from the trans-activating transcriptional acti-
vator (TAT) protein], antennapedia, arginine-rich peptides and
others, promote enhanced cellular uptake of molecules attached
to them. The majority of cell-penetrating peptides enter cells
via one of the endocytotic routes (Bechara and Sagan, 2013),
although a number of reports indicate the possibility of direct
diffusion across the membrane lipid bilayer. Commonly in these
cases a hydrophobic motif is added to the peptide (Carrigan and
Imperiali, 2005; Takayama et al., 2009), which, unfortunately,
increases the probability of membrane destabilization and toxi-
city (Chan et al., 2006). Furthermore, cell-penetrating peptides
are positively charged, which is also associated with the enhanced
toxicity, limiting their use. Microbial peptides induce permeabi-
lization of the plasma membranes and act cooperatively, which
is non-advantageous for drug delivery systems. In each of these
cases, there is no preferential tumor targeting, since the peptides
enter both diseased and normal cells.
The folding and insertion into membrane of constitutive
membrane proteins is facilitated by complex molecular machines
in vivo, including the translocon that places most transmem-
brane helices across the bilayer (Van Den Berg et al., 2004;
White and Von Heijne, 2004; Osborne et al., 2005). However,
non-constitutive membrane proteins can insert transmembrane
helices (TMs) into a lipid bilayer without assistance. Because the
spontaneous insertion and folding of a TM peptide into a lipid
bilayer approaches a free energy minimum, an insertion event is
accompanied by the release of energy. The moderately hydropho-
bic TM forming peptides such pHLIPs might be considered as the
basis for a novel class of delivery agents: single-molecular trans-
porters. The membrane-associated folding of pHLIPs is accom-
panied by the release of about 2 kcal/mol of energy, which could
be used as a biasing potential to favor the movement of polar,
cell-impermeable cargo molecules across membrane into a cyto-
plasm. A significant feature of the process of peptide folding into
a membrane is that it ensures a much higher cooperativity of
the transition compared to the simple pH-driven diffusion of
weak bases across a membrane. Translocation is selective for low
pH, and various types of cargo molecules attached by disulfides
to the inserting end of pHLIP (in most cases the C-terminus)
can be transported into a cell and released in cytoplasm. We
have demonstrated that pHLIP can translocate fluorescent dyes,
cyclic peptides, polar toxins and peptide nucleic acids into cancer
cells, and the properties of translocatable molecules can signifi-
cantly violate Lipinski’s rules, being larger and much more polar
(Reshetnyak et al., 2006; Thevenin et al., 2009; An et al., 2010;
Wijesinghe et al., 2011; Moshnikova et al., 2013). The translo-
cation is fast (seconds to minutes), pH- and concentration-
dependent and can bemodulated by tuning of the hydrophobicity
of the pHLIP inserting end. Compounds such as phalloidin and
α-amanitin have not been considered as anti-cancer therapeutic
agents, since they cannot cross cellular membranes (LogPo/wis
about−1.5 and theMW is about 800–1000 gmol−1). These toxins
are selectively taken up by hepatocytes, leading to liver damage,
since hepatocytes possess special transporting systems to translo-
cate small cyclic molecules (Magdalan et al., 2010; Santi et al.,
2012). Recently, it has been demonstrated that amanitin con-
jugated with an anti-human epithelial cell adhesion antibody
induces inhibition of cell proliferation and suppression of pan-
creatic tumor growth (Moldenhauer et al., 2012). Conjugation
of phallo- and amanita toxins to the pHLIP’s inserting end via
cleavable bond also leads to cell death in a low extracellular
pH environment. The major mechanism of polar cargo delivery
is direct translocation across the plasma membrane by pHLIP
and cleavage of S-S bond in the reducing environment of the
cytoplasm (other types of bonds might be used). Amanitin con-
jugated to pHLIP via non-cleavable cross-linkers or attached to
the non-inserting end of the peptide was not able to induce cell
death.
pHLIP-MEDIATED DELIVERY OF NANOPARTICLES AND
LIPOSOMES
The pHLIP technology can also substantially improve the delivery
of nanoparticles and liposomes to acidic diseased tissue (Davies
et al., 2012; Sosunov et al., 2013; Wijesinghe et al., 2013; Yao
et al., 2013a,b). The intratumoral and intravenous administration
of gold nanoparticles conjugated with pHLIP both demonstrated
6-fold enhancement of tumor uptake compared to gold nanopar-
ticles with no pHLIP (Yao et al., 2013a). Statistically significant
reduction of gold accumulation was observed in acidic tumors
and kidneys when pH-nonsensitive K-pHLIP (where Asp residues
are replaced by Lys) was used as a vehicle, suggesting an important
role of pH in the pHLIP-mediated targeting of gold nanoparticles.
Gold nanoparticles delivered to a tumor might be used for local
enhancement of radiation therapy.
We have also developed pH-sensitive, “fusogenic” pHLIP-
coated liposomes (Wijesinghe et al., 2013; Yao et al., 2013b).
The presence of pHLIP on the surfaces of liposomes enhances
membrane fusion and lipid exchange in a pH dependent fash-
ion, leading to an increase of cellular uptake and payload release,
and consequent inhibition of cell proliferation by liposomes
containing ceramide. Using two murine ischemia models we
show that pHLIP-coated liposomes bind acidic ischemic but not
normal regions of myocardium, while liposomes coated with
PEG showed no preference in targeting of acidic ischemic tissue
(Sosunov et al., 2013).
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FIGURE 2 | Schematic presentation of pHLIP-coated liposome entry into
a cell. pHLIP coated Liposomes with encapsulated polar cargo molecules or
carrying hydrophobic cargoes in their bilayers can deliver payloads to cell
membranes and cytoplasms. The acidity of diseased tissue results in
pHLIP-mediated fusion of liposomes with plasma membranes at low
extracellular pH (A) or fusion with endosomal membranes (B).
pHLIP-coated liposomes have been used for selective deliv-
ery of gramicidin nano-pores to cancer cells (Wijesinghe
et al., 2013). Gramicidin channels inserted into the cancer
cell membranes allow a flux of protons into the cytoplasm,
and also disrupt the transmembrane balance of other mono-
valent cations, which induces cell apoptosis. Selective incorpo-
ration of functional gramicidin channels opens an opportunity
for the delivery of other membrane peptides and proteins,
which might find wide application in biotechnology and
medicine.
In contrast to the pHLIP action as a single-molecule trans-
porter when a single cargo molecule is attached to the single
pHLIP peptide, multiple pHLIPs on the surfaces of liposomes or
lipid-coated nanoparticles will interact with cellular membranes
cooperatively, promoting membrane deformation, and tension.
This binding will lead to lipid exchange, enhanced cellular uptake
and/or direct fusion accompanied by the delivery of hydropho-
bic molecules to cellular membranes and polar cargo molecules
to cytoplasm (Figures 2A,B). These processes are initiated in the
acidic environment of diseased tissue, or, in the case of endocy-
totic uptake, will be even more effectively promoted by the low
pH of endosomes/lysosomes, leading to the cytoplasmic release
of cargo.
CONCLUDING REMARKS
Peptides of pHLIP family can be used to target cells dis-
eased tissues as a result of extracellular acidity. Tuning the
properties of pHLIP by sequence variation allows alteration
of pharmacokinetics and targeting ability. pHLIPs conjugated
with cell-impermeable cargoes are a novel class of delivery
agents: single-molecule transporters for direct cytoplasmic deliv-
ery of polar cargo molecules into cells in acidic, diseased tis-
sues. Multiple pHLIPs on the surfaces of nano-sized particles
promote pH-mediated distortion of cellular membranes, lead-
ing to the enhanced delivery of payloads to cytosols or cellular
membranes.
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